ERBB2 and neoplasm: Although adjuvant systemic therapy is decided based on molecular subtype, risk categories are defined using age, tumor size, grade, extensive peritumoral vascular invasion, hormonal receptors, human epidermal growth factor receptor 2 (HER2)-positivity, and nodal metastasis to identify risk of recurrence [2].